230 related articles for article (PubMed ID: 32466683)
1. WJOG10517G: a multicenter Phase II study of mFOLFOX6 in gastric cancer patients with severe peritoneal metastases.
Masuishi T; Nakajima TE; Yamazaki K; Hironaka S; Kudo C; Yoshimura K; Muro K
Future Oncol; 2020 Jul; 16(20):1417-1424. PubMed ID: 32466683
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G).
Nakajima TE; Yamaguchi K; Boku N; Hyodo I; Mizusawa J; Hara H; Nishina T; Sakamoto T; Shitara K; Shinozaki K; Katayama H; Nakamura S; Muro K; Terashima M
Gastric Cancer; 2020 Jul; 23(4):677-688. PubMed ID: 32036492
[TBL] [Abstract][Full Text] [Related]
3. Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake.
Iwasa S; Goto M; Yasui H; Nishina T; Takahari D; Nakayama N; Taira K; Kusaba H; Fuse N; Hironaka S; Shimada Y; Nakajima TE
Jpn J Clin Oncol; 2012 Sep; 42(9):787-93. PubMed ID: 22782960
[TBL] [Abstract][Full Text] [Related]
4. First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake.
Hara H; Kadowaki S; Asayama M; Ooki A; Yamada T; Yoshii T; Yamaguchi K
Int J Clin Oncol; 2018 Apr; 23(2):275-280. PubMed ID: 29039072
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G.
Arai H; Inoue E; Yamaguchi K; Boku N; Hara H; Nishina T; Tsuda M; Shitara K; Shinozaki K; Nakamura S; Hyodo I; Muro K; Sasako M; Terashima M; Nakajima TE
Cancer Med; 2021 Nov; 10(21):7673-7682. PubMed ID: 34655175
[TBL] [Abstract][Full Text] [Related]
6. Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study.
Arai H; Iwasa S; Boku N; Kawahira M; Yasui H; Masuishi T; Muro K; Minashi K; Hironaka S; Fukuda N; Takahari D; Nakajima TE
BMC Cancer; 2019 Jul; 19(1):652. PubMed ID: 31269916
[TBL] [Abstract][Full Text] [Related]
7. FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis.
Masuishi T; Kadowaki S; Kondo M; Komori A; Sugiyama K; Mitani S; Honda K; Narita Y; Taniguchi H; Ura T; Ando M; Mishima H; Muro K
Anticancer Res; 2017 Dec; 37(12):7037-7042. PubMed ID: 29187492
[TBL] [Abstract][Full Text] [Related]
8. Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial.
Murono K; Nagata H; Ishimaru K; Emoto S; Kaneko M; Hiyoshi M; Sasaki K; Otani K; Shuno Y; Nishikawa T; Tanaka T; Hata K; Kawai K; Nozawa H; Muro K; Ishihara S
Cancer Chemother Pharmacol; 2019 Jan; 83(1):145-150. PubMed ID: 30386886
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A;
Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560
[TBL] [Abstract][Full Text] [Related]
10. First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer.
Iwasa S; Nakajima TE; Nakamura K; Takashima A; Kato K; Hamaguchi T; Yamada Y; Shimada Y
Gastric Cancer; 2012 Jan; 15(1):21-6. PubMed ID: 21573919
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination.
Imazawa M; Kojima T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yasui H; Yamazaki K; Taku K
Gastric Cancer; 2009; 12(3):153-7. PubMed ID: 19890695
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial.
Yamao T; Shimada Y; Shirao K; Ohtsu A; Ikeda N; Hyodo I; Saito H; Iwase H; Tsuji Y; Tamura T; Yamamoto S; Yoshida S
Jpn J Clin Oncol; 2004 Jun; 34(6):316-22. PubMed ID: 15333683
[TBL] [Abstract][Full Text] [Related]
13. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
14. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.
Munemoto Y; Nakamura M; Takahashi M; Kotaka M; Kuroda H; Kato T; Minagawa N; Noura S; Fukunaga M; Kuramochi H; Touyama T; Takahashi T; Miwa K; Satake H; Kurosawa S; Miura T; Mishima H; Sakamoto J; Oba K; Nagata N
Eur J Cancer; 2019 Sep; 119():158-167. PubMed ID: 31445198
[TBL] [Abstract][Full Text] [Related]
15. [Chemotherapeutic Strategies for Peritoneal Dissemination of Gastric Cancer].
Matsushima T; Wakatsuki T; Takahari D; Chin K; Yamaguchi K
Gan To Kagaku Ryoho; 2016 Dec; 43(13):2477-2480. PubMed ID: 28028252
[TBL] [Abstract][Full Text] [Related]
16. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
Oh SY; Kwon HC; Lee S; Lee DM; Yoo HS; Kim SH; Jang JS; Kim MC; Jeong JS; Kim HJ
Jpn J Clin Oncol; 2007 Dec; 37(12):930-5. PubMed ID: 18211984
[TBL] [Abstract][Full Text] [Related]
17. Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106).
Shirao K; Boku N; Yamada Y; Yamaguchi K; Doi T; Goto M; Nasu J; Denda T; Hamamoto Y; Takashima A; Fukuda H; Ohtsu A;
Jpn J Clin Oncol; 2013 Oct; 43(10):972-80. PubMed ID: 24014884
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance status.
Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Esenkaya A; Uzunoglu S; Cicin I
Asian Pac J Cancer Prev; 2015; 16(6):2355-9. PubMed ID: 25824764
[TBL] [Abstract][Full Text] [Related]
19. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).
Rovers KP; Bakkers C; Simkens GAAM; Burger JWA; Nienhuijs SW; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; Ayez N; de Boer NL; van Meerten E; Tuynman JB; Kusters M; Sluiter NR; Verheul HMW; van der Vliet HJ; Wiezer MJ; Boerma D; Wassenaar ECE; Los M; Hunting CB; Aalbers AGJ; Kok NFM; Kuhlmann KFD; Boot H; Chalabi M; Kruijff S; Been LB; van Ginkel RJ; de Groot DJA; Fehrmann RSN; de Wilt JHW; Bremers AJA; de Reuver PR; Radema SA; Herbschleb KH; van Grevenstein WMU; Witkamp AJ; Koopman M; Haj Mohammad N; van Duyn EB; Mastboom WJB; Mekenkamp LJM; Nederend J; Lahaye MJ; Snaebjornsson P; Verhoef C; van Laarhoven HWM; Zwinderman AH; Bouma JM; Kranenburg O; van 't Erve I; Fijneman RJA; Dijkgraaf MGW; Hemmer PHJ; Punt CJA; Tanis PJ; de Hingh IHJT; ;
BMC Cancer; 2019 Apr; 19(1):390. PubMed ID: 31023318
[TBL] [Abstract][Full Text] [Related]
20. A combination immunochemotherapy of 5-fluorouracil, cisplatin, leucovorin, and OK-432 for advanced and recurrent gastric carcinoma.
Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Noguchi Y
Hepatogastroenterology; 2003; 50(54):2259-63. PubMed ID: 14696512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
